Cloned (Comment) | Organism |
---|---|
quantitative enzyme expression PCR analysis | Homo sapiens |
quantitative enzyme expression PCR analysis | Rattus norvegicus |
Protein Variants | Comment | Organism |
---|---|---|
additional information | enzyme silencing by CSE-specific siRNA | Rattus norvegicus |
additional information | enzyme silencing by CSE-specific siRNA, treatment with acetoacetate and high D-glucose of 25 mM causes a significant decrease in enzyme protein expression compared with those in normal controls, while 4-hydroxybutyrate has no effect | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
acetoacetate | treatment with 0.025-0.035 mM H2O2, 4-8 mM acetoacetate and high D-glucose of 25 mM causes a significant decrease in enzyme protein expression, enzyme activity, and H2S levels, and an increase in intracellular reactive oxygen species production compared with those in normal controls | Homo sapiens | |
D-glucose | treatment with 0.025-0.035 mM H2O2, 4-8 mM acetoacetate and high D-glucose of 25 mM causes a significant decrease in enzyme protein expression, enzyme activity, and H2S levels, and an increase in intracellular reactive oxygen species production compared with those in normal controls | Homo sapiens | |
H2O2 | treatment with 0.025-0.035 mM H2O2, 4-8 mM acetoacetate and high D-glucose of 25 mM causes a significant decrease in enzyme protein expression, enzyme activity, and H2S levels, and an increase in intracellular reactive oxygen species production compared with those in normal controls | Homo sapiens | |
additional information | no inhibition by 4-hydroxybutyrate | Homo sapiens | |
streptozotocin | livers from streptozotocin-treated type I diabetic rats have lower levels of enzyme protein expression, enzyme activity, reduced tissue H2S formation, and increased reactive oxygen species production compared with those of controls | Rattus norvegicus |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
L-cystathionine + H2O | Homo sapiens | - |
L-cysteine + 2-oxobutanoate + NH3 | - |
r | |
L-cystathionine + H2O | Rattus norvegicus | - |
L-cysteine + 2-oxobutanoate + NH3 | - |
r | |
L-cystathionine + H2O | Rattus norvegicus Sprague-Dawley | - |
L-cysteine + 2-oxobutanoate + NH3 | - |
r | |
L-cysteine + H2O | Homo sapiens | - |
H2S + pyruvate + NH3 | - |
? | |
L-cysteine + H2O | Rattus norvegicus | - |
H2S + pyruvate + NH3 | - |
? | |
L-cysteine + H2O | Rattus norvegicus Sprague-Dawley | - |
H2S + pyruvate + NH3 | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Rattus norvegicus | - |
- |
- |
Rattus norvegicus Sprague-Dawley | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
liver | of type 1 diabetic rats | Rattus norvegicus | - |
monocyte | - |
Homo sapiens | - |
peripheral blood mononuclear cell | peripheral blood mononuclear cells, PBMC, isolated from healthy subjects and type 1 diabetic patients | Homo sapiens | - |
U-937 cell | a pro-monocytic cell line | Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
L-cystathionine + H2O | - |
Homo sapiens | L-cysteine + 2-oxobutanoate + NH3 | - |
r | |
L-cystathionine + H2O | - |
Rattus norvegicus | L-cysteine + 2-oxobutanoate + NH3 | - |
r | |
L-cystathionine + H2O | - |
Rattus norvegicus Sprague-Dawley | L-cysteine + 2-oxobutanoate + NH3 | - |
r | |
L-cysteine + H2O | - |
Homo sapiens | H2S + pyruvate + NH3 | - |
? | |
L-cysteine + H2O | - |
Rattus norvegicus | H2S + pyruvate + NH3 | - |
? | |
L-cysteine + H2O | - |
Rattus norvegicus Sprague-Dawley | H2S + pyruvate + NH3 | - |
? |
Synonyms | Comment | Organism |
---|---|---|
CSE | - |
Homo sapiens |
CSE | - |
Rattus norvegicus |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
37 | - |
assay at | Homo sapiens |
37 | - |
assay at | Rattus norvegicus |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
7.4 | - |
assay at | Homo sapiens |
7.4 | - |
assay at | Rattus norvegicus |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
pyridoxal 5'-phosphate | - |
Homo sapiens | |
pyridoxal 5'-phosphate | - |
Rattus norvegicus |
Organism | Comment | Expression |
---|---|---|
Rattus norvegicus | livers from streptozotocin-treated type I diabetic rats have lower levels of enzyme protein expression, enzyme activity, reduced tissue H2S formation, and increased reactive oxygen species production compared with those of controls | down |
General Information | Comment | Organism |
---|---|---|
malfunction | both hyperglycemia and hyperketonemia mediate a reduction in enzyme expression and activity, which can contribute to the impaired H2S signaling associated with diabetes. Livers from streptozotocin-treated type I diabetic rats have lower levels of enzyme protein expression, enzyme activity, reduced tissue H2S formation, and increased reactive oxygen species production compared with those of controls | Rattus norvegicus |
malfunction | both hyperglycemia and hyperketonemia mediate a reduction in enzyme expression and activity, which can contribute to the impaired H2S signaling associated with diabetes. Treatment with 0.025-0.035 mM H2O2, 4-8 mM acetoacetate and high D-glucose of 25 mM causes a significant decrease in enzyme protein expression, enzyme activity, and H2S levels, and an increase in intracellular reactive oxygen species production compared with those in normal controls | Homo sapiens |